华兰疫苗
(301207)
| 流通市值：23.24亿 | | | 总市值：98.63亿 |
| 流通股本：1.42亿 | | | 总股本：6.01亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 24,282,534.72 | 1,127,812,323.85 | 957,363,018.62 | 35,528,955.73 |
| 营业收入 | 24,282,534.72 | 1,127,812,323.85 | 957,363,018.62 | 35,528,955.73 |
| 二、营业总成本 | 49,573,022.32 | 961,283,918.27 | 757,727,172.19 | 122,298,010.07 |
| 营业成本 | 3,400,793.07 | 212,558,788.13 | 181,380,089.52 | 8,731,017.68 |
| 税金及附加 | 1,458,933.06 | 10,606,122.82 | 8,383,073.02 | 3,495,176.16 |
| 销售费用 | 14,617,192.32 | 501,385,044.85 | 411,829,871.25 | 22,169,706.13 |
| 管理费用 | 7,947,905.52 | 81,157,726.37 | 83,284,696.66 | 48,012,628.2 |
| 研发费用 | 22,115,565.91 | 162,640,277.74 | 80,510,272.88 | 46,835,795.33 |
| 财务费用 | 32,632.44 | -7,064,041.64 | -7,660,831.14 | -6,946,313.43 |
| 其中:利息费用 | 1,316,666.68 | 6,100,000.02 | 4,400,000.02 | 2,866,666.68 |
| 其中:利息收入 | 1,313,039.44 | 13,215,392.6 | 12,124,492.32 | 9,800,729.75 |
| 加:公允价值变动收益 | 5,452,133.52 | 24,300,582.77 | 19,027,316.14 | 14,755,500.21 |
| 加:投资收益 | 20,064,785.01 | 76,072,994.64 | 55,812,973.56 | 34,603,494.93 |
| 资产处置收益 | - | -140,144.03 | -140,144.03 | -140,144.03 |
| 资产减值损失(新) | 1,046,468.97 | -74,225,065.72 | - | - |
| 信用减值损失(新) | 32,636,845.67 | 9,429,587.47 | 22,493,940.1 | 57,127,412.78 |
| 其他收益 | 2,558,547.64 | 12,889,666.46 | 9,041,487.2 | 5,003,574.64 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 36,468,293.21 | 214,856,027.17 | 305,871,419.4 | 24,580,784.19 |
| 加:营业外收入 | - | 1,603,558.25 | 1,547,266.25 | 1,547,266.25 |
| 减:营业外支出 | 1,130,559.99 | 1,913,859.17 | 1,517,587.49 | 969,935.48 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 35,337,733.22 | 214,545,726.25 | 305,901,098.16 | 25,158,114.96 |
| 减:所得税费用 | 2,560,661.08 | 9,030,410.5 | 38,541,370.3 | -116,322.1 |
| 六、净利润 | 32,777,072.14 | 205,515,315.75 | 267,359,727.86 | 25,274,437.06 |
| 持续经营净利润 | 32,777,072.14 | 205,515,315.75 | 267,359,727.86 | 25,274,437.06 |
| 归属于母公司股东的净利润 | 32,777,072.14 | 205,515,315.75 | 267,359,727.86 | 25,274,437.06 |
| (一)基本每股收益 | 0.06 | 0.34 | 0.45 | 0.04 |
| (二)稀释每股收益 | 0.06 | 0.34 | 0.45 | 0.04 |
| 九、综合收益总额 | 32,777,072.14 | 205,515,315.75 | 267,359,727.86 | 25,274,437.06 |
| 归属于母公司股东的综合收益总额 | 32,777,072.14 | 205,515,315.75 | 267,359,727.86 | 25,274,437.06 |
| 公告日期 | 2025-04-28 | 2025-03-29 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |